Delving into the Latest Updates on Allogeneic bone-marrow derived mesenchymal stem cells (University of Miami) with Synapse

Overview

Basic Info

Drug Type

Mesenchymal stem cell therapy

Synonyms-

Target-

Action-

Mechanism

Cell replacements

Therapeutic Areas

Cardiovascular DiseasesEndocrinology and Metabolic DiseaseOther Diseases+ [3]

Active Indication-

Inactive Indication

AsthmaCrohn DiseaseEndothelial dysfunction+ [3]

Originator Organization

University of Miami

Active Organization-

Inactive Organization

University of Miami

License Organization-

Drug Highest PhaseDiscontinuedPhase 1/2

First Approval Date-

Regulation-

Login to view timeline

To evaluate the role of allogeneic mesenchymal stem cells for treatment of perianal fistulizing Crohn disease.
Twenty (20) Crohn's disease patients with complex or multiple perianal or rectovaginal fistulas will be included and will be scheduled to undergo peri-fistula injections after meeting all inclusion/exclusion criteria's at baseline.
Following the Pilot Phase of four (4) subjects, sixteen (16) subjects are scheduled to undergo perianal injections and after meeting all inclusion/exclusion criteria's, will be evaluated at baseline.

Start Date01 Dec 2019

Sponsor / Collaborator

University of Miami

NCT03059355

/ TerminatedPhase 1/2IIT

A Phase I/II, Randomized, Placebo-controlled Comparative Study to Evaluate the Safety and Potential Efficacy of Intravenous Infusion of Umbilical Cord Tissue (UC) Derived Mesenchymal Stem Cells (MSCs) Versus Bone Marrow (BM) Derived MSCs to Evaluate Cytokine Suppression in Patients With Chronic Inflammation Due to Metabolic Syndrome.

This study is to compare the safety and efficacy of UCMSCs and BMMSCs administered intravenously in patients to evaluate cytokine suppression in patients with chronic inflammation. Cells administered via intravenous infusion (IV) and will be tested in 37 patients in two phases (Pilot and Randomized).

Start Date12 Apr 2018

Sponsor / Collaborator

University of Miami

[+1]

NCT03137199

/ TerminatedPhase 1IIT

A Phase I, Trial to Evaluate the Safety, Tolerability, and Potential Efficacy of Allogeneic Human Mesenchymal Stem Cell Infusion in Patients With Mild Asthma

A Phase 1 investigation will be performed to test the safety of two doses of bone marrow-derived MSCs (20,000,000 and 100,000,000) administered via peripheral intravenous infusion.

Start Date22 Jun 2017

Sponsor / Collaborator

University of Miami

[+1]

100 Clinical Results associated with Allogeneic bone-marrow derived mesenchymal stem cells (University of Miami)

Login to view more data

100 Translational Medicine associated with Allogeneic bone-marrow derived mesenchymal stem cells (University of Miami)

Login to view more data

100 Patents (Medical) associated with Allogeneic bone-marrow derived mesenchymal stem cells (University of Miami)

Login to view more data

100 Deals associated with Allogeneic bone-marrow derived mesenchymal stem cells (University of Miami)

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Endothelial dysfunction	Phase 2	United States	University of Miami	12 Apr 2018
Inflammation	Phase 2	United States	University of Miami	12 Apr 2018
Metabolic Syndrome	Phase 2	United States	University of Miami	12 Apr 2018
Crohn Disease	Phase 1	United States	University of Miami	01 Dec 2019
Asthma	Phase 1	United States	University of Miami	22 Jun 2017
Non-cystic fibrosis bronchiectasis	Phase 1	United States	University of Miami	04 Feb 2016

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03059355 (CERES, CTgov)	Phase 1/2	Metabolic Syndrome \| Inflammation \| Endothelial dysfunction	14	UCMSCs (Pilot Phase: Group 1 (UCMSCs - 20 Million))	wkicldgvfz = kntdbyziqp sfritswtvg (gvpexrxjfr, rhauwvispl - dxkfvvgnii) View more	-	08 Nov 2022
				BMMSCs (Pilot Phase: Group 2 (BMMSCs - 20 Million))	wkicldgvfz = azkgaqtizb sfritswtvg (gvpexrxjfr, vberloispt - aaylihvepb) View more